Dian Diagnostics has reached a cooperation with Sir Run Run Shaw Hospital to jointly promote the transformation of medical achievements related to immunotherapy biomarkers for hepatocellular carcinoma

Zhitong
2025.09.11 10:02

On September 11th, Dian Diagnostics Technology Group Co., Ltd. signed a transformation project agreement with the Sir Run Run Shaw Hospital affiliated with Zhejiang University School of Medicine for "A Gene Model Construction Method and Application for Identifying New Subtypes of Hepatocellular Carcinoma," jointly promoting the transformation of medical achievements related to immunotherapy biomarkers for hepatocellular carcinoma. The results of this transformation focus on utilizing omics and AI technology to construct a new subtype identification model for HCC based on 29 genes. The immunotherapy response rate for patients with this subtype is significantly higher than that of non-HCC-1 subtype patients. This achievement helps to screen potential beneficiaries of immunotherapy, avoid ineffective treatments, and save medical resources. Currently, a nationwide multi-center study based on this project is underway

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer